Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

American Journal of Hematology

Volumn 91, Issue 11, 2016, Pages 1096-1101

  Maurer, Matthew J ^a   Bachy, Emmanuel ^b   Ghesquières, Hervé ^b,c   Ansell, Stephen M ^a   Nowakowski, Grzegorz S ^a   Thompson, Carrie A ^a   Inwards, David J ^a   Allmer, Cristine ^a   Chassagne Clément, Catherine ^c   Nicolas Virelizier, Emmanuelle ^c   Sebban, Catherine ^c   Lebras, Laure ^b   Sarkozy, Clementine ^b   Macon, William R ^a   Feldman, Andrew L ^a   Syrbu, Sergei I ^d   Traverse Glehan, Alexandra ^b   Coiffier, Bertrand ^b   Slager, Susan L ^a   Weiner, George J ^e   Witzig, Thomas E ^a   Habermann, Thomas M ^b   Salles, Gilles ^b   Cerhan, James R ^a   Link, Brian K ^e   more..

^a MAYO CLINIC   (United States)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; STANDARDIZED MORTALITY RATIO; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; REGISTER; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84984829657     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24492     Document Type: Article

References (28)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265–276.
2. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:5165–5169.
3. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013;31:3272–3278. Prepublished on 2013/07/31 as DOI 10.1200/JCO.2012.48.3990.
4. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, et al. Transformed non-Hodgkin lymphoma in the rituximab era: Analysis of the NCCN outcomes database. Br J Haematol 2013;163:487–495. Prepublished on 2013/10/12 as DOI 10.1111/bjh.12570.
5. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27:1607–1614. 10.1200/jco.2008.17.1561.
6. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423. 10.1182. /blood-2004-08-3175.
7. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824–4831. 10.1182/blood-2008-04-153189.
8. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone. Blood 2005;106:3725–3732. 10.1182/blood-2005-01-0016.
9. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–1992. 10.1200/jco.2006.06.4618.
10. Keegan THM, McClure LA, Foran JM, Clarke CA. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: A population-based study. J Clin Oncol 2009;27:3044–3051. 10.1200/jco.2008.18.8052.
11. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582–1589. Prepublished on 2006/04/01 as DOI 10.1200/JCO.2005.03.3696.
12. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452. 10.1200/jco.2005.03.1674.
13. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience. Blood 2013;122:981–987.10.1182/blood-2013-03-491514.
14. Nooka AK, Nabhan C, Zhou X, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): A prospective US patient cohort treated predominantly in community practices. Annals Oncol 2013;24:441–448. Prepublished on 2012/10/09 as DOI 10.1093/annonc/mds429.
15. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265. 10.1182/blood-2003-12-4434.
16. Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therpay in patients with follicular lymphonma: A pooled analysis of central scan review in three multicentre studies. Lancet Haematol 2014;1:e17–e27.
17. Sargent Daniel J, Shi Qian, De Bedout Sabine, et al. Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts). J Clin Oncol 2015;33: abstr 8504.
18. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. J Clin Oncol 2015;33:2516–2522. 10.1200/jco.2014.59.7534.
19. Maurer MJ, Ghesquières H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014;32:1066–1073. 10.1200/jco.2013.51.5866.
20. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412–417. Prepublished on 2009/12/17. as DOI 10.1200/JCO.2009.23.4245.
21. Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 2010;28:4191–4198.
22. Nicolas-Virelizier E, Segura-Ferlay C, Ghesquieres H, et al. Impact of the introduction of rituximab in first-line follicular lymphoma: A retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up. Hematological Oncol 2015;33:1–8. Prepublished on 2014/02/06 as DOI 10.1002/hon.2130.
23. Therneau TM. A Package for Survival Analysis in S. version 2.38, http://CRAN.R-project.org/package=survival. (ed version 2.38); 2015.
24. Jais J-P, Varet H. Survexp.fr: Relative survival, AER and SMR based on French death rates (R package version 1.0). http://cran.r-project.org/web/packages/survexp.fr/index.html 2013.
25. Therneau T, Sicks J, Bergstralh EJ. O. Technical Report Series No. 52, Expected Survival Based on Hazard Rates. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, March 1994.
26. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag; 2000.
27. Verheul HA, Dekker E, Bossuyt P, Moulijn AC, Dunning AJ. Background mortality in clinical survival studies. Lancet 1993;341:872–875. Prepublished on 1993/04/03 as DOI.
28. Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc 1983;78:1–12.